Differential Carbohydrate Recognition by Campylobacter jejuni Strain 11168: Influences of Temperature and Growth Conditions by Day, Christopher J. et al.
Differential Carbohydrate Recognition by Campylobacter
jejuni Strain 11168: Influences of Temperature and
Growth Conditions
Christopher J. Day, Joe Tiralongo*, Regan D. Hartnell, Carie-Anne Logue, Jennifer C. Wilson, Mark von
Itzstein, Victoria Korolik*
Institute for Glycomics, Griffith University Gold Coast Campus, Queensland, Australia
Abstract
The pathogenic clinical strain NCTC11168 was the first Campylobacter jejuni strain to be sequenced and has been a widely
used laboratory model for studying C. jejuni pathogenesis. However, continuous passaging of C. jejuni NCTC11168 has been
shown to dramatically affect its colonisation potential. Glycan array analysis was performed on C. jejuni NCTC11168 using
the frequently passaged, non-colonising, genome sequenced (11168-GS) and the infrequently passaged, original, virulent
(11168-O) isolates grown or maintained under various conditions. Glycan structures recognised and bound by C. jejuni
included terminal mannose, N-acetylneuraminic acid, galactose and fucose. Significantly, it was found that only when
challenged with normal oxygen at room temperature did 11168-O consistently bind to sialic acid or terminal mannose
structures, while 11168-GS bound these structures regardless of growth/maintenance conditions. Further, binding of un-
capped galactose and fucosylated structures was significantly reduced when C. jejuni was maintained at 25uC under
atmospheric oxygen conditions. These binding differences identified through glycan array analysis were confirmed by the
ability of specific lectins to competitively inhibit the adherence of C. jejuni to a Caco-2 intestinal cell line. Our data suggests
that the binding of mannose and/or N-acetylneuraminic acid may provide the initial interactions important for colonisation
following environmental exposure.
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Introduction
Carbohydrates (or glycans) that modify proteins and lipids play
a key role in numerous cell recognition events, including those
involved in the regulation of the immune system [1], and in the
attachment of pathogenic organisms to host tissue [2]. Protein-
carbohydrate interactions have been identified as adherence
factors for numerous commensal and pathogenic bacteria
including Pseudomonas aeruginosa[3,4,5], Helicobacter pylori
[6,7,8,9,10] and Escherichia coli [11]. The identification and
characterisation of carbohydrate binding proteins (or lectins) has
been greatly enhanced through the development of glycan array
technology [12]. Glycan arrays are fast becoming the technique of
choice for identifying and elucidating the specificity of lectins
[12,13,14], and have been successfully used to identify and
characterise the interactions of viruses and bacteria with their
glycan receptors [12,15].
Campylobacter jejuni, the most prevalent cause of gastroenteritis in
developed countries, is a highly motile, Gram-negative spiral rod
that requires microaerobic conditions for growth [16,17]. C. jejuni
is a zoonotic pathogen, being a commensal organism in poultry
and other wildlife. Poorly prepared poultry products represent the
most common source of human infection; however, infection can
also arise from contaminated water and unpasteurised milk [16].
C. jejuni is a thermophilic organism, requiring temperatures in the
range of 32uCt o4 5 uC for growth, but it can also survive at lower
temperatures in the environment [18].
The pathogenic clinical isolate NCTC11168 was the first C.
jejuni strain to be sequenced and has been a widely used laboratory
model for studying C. jejuni pathogenesis [19]. However, more
recent investigations have shown that continuous passaging of C.
jejuni NCTC11168 dramatically affects its colonisation potential.
That is, long-term passaging and oxygen-adaptation of the 11168-
genome sequenced strain (11168-GS) leads to poor colonisation
potential in chicken models [20,21], while the same strain
infrequently passaged (11168-original, 11168-O) remains a potent
coloniser of chickens. Moreover, C. jejuni 11168-O was found to be
more adherent and invasive in in vitro infection models and was
observed to be more motile than 11168-GS [21]. Microscopic
analysis of the two strains also demonstrated a shift in phenotypic
appearance, with 11168-GS existing as straight rods rather than
the normal spiral-shaped rod of 11168-O. Other differences were
also noted in gene expression, with particular changes in genes
involved in oxygen metabolism; however, serotyping, genotyping
and subtractive hybridisation found the two strains to be clonal
[21].
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source, instead relying on amino acids such as aspartate and serine
[22]. Any observed carbohydrate binding can therefore be
attributed to interactions important for adherence and/or
colonisation rather than for energy acquisition. The differential
adherence, invasion and colonisation observed for C. jejuni 11168-
GS and 11168-O suggests that significant differences exist in how
the two strains interact with host cells. Bacteria-host interactions
depend not only on bacterial motility, but also on bacterial
adherence factors such as lectins, and the surface composition of
the host cell, including the degree and type of glycosylation [2,23].
The adherence phenotypes observed for C. jejuni 11168-GS and
11168-O may therefore reflect differential host cell carbohydrate
recognition. The carbohydrate-mediated interaction of C. jejuni
with host cell glycans has been reported. C. jejuni, for example, is
chemotactic to fucose (Fuc) [24], and is known to interact with
glycoproteins of the intestinal tract, such as mucins [25] and Lewis
B-like structures present on human milk proteins [26,27]. The
functional significance of these interactions is not entirely
understood, and the complete range of sugars recognised, as well
as the C. jejuni lectins involved, are yet to fully be identified.
This study aims to identify glycan structures bound by C. jejuni
11168-GS and 11168-O strains using glycan array technology and
in vitro cell adherence assays, and to explore how these interactions
are influenced by changes in temperature and oxygen condition.
Conditions were chosen to mimic those encountered by C. jejuni
through various growth and survival phases, including conditions
required for survival in the environment (25uC, normal O2), and in
mammalian (37uC, microaerophilic) and avian (42uC, microaero-
philic) hosts (Table 1). Here we report that distinct growth and
survival conditions dramatically alter the degree and specificity of
C. jejuni binding to various carbohydrate structures, including
differential binding to mannose (Man) and N-acetylneuraminic
acid (Neu5Ac)-containing glycans.
Results
Glycan array analysis
Glycan arrays were performed using the non-colonising genome
sequenced isolate of the C. jejuni strain NCTC11168 (11168-GS)
and the colonising isolate 11168-O, grown or maintained at
varying conditions as outlined in the Materials and Methods
(summarised in Table 1). Our analyses found that the binding of C.
jejuni strains 11168-GS and 11168-O to galactose (Gal), Man, Fuc,
and Neu5Ac-containing glycans was significantly affected by the
conditions under which the bacteria were grown/maintained. In
addition, significant differences in the carbohydrate-binding
specificity were also observed between C. jejuni 11168-GS and
11168-O.
Binding to terminal Gal/GalNAc
C. jejuni 11168-GS maintained at 25uC (11168-GS 25uC)
exhibited little or no binding to terminal Gal-containing structures
present on the array. Of particular note, no binding to the core O-
glycan Tn antigen (Galb1-3GalNAca1-O-Ser; 1M) or glycans
terminated with Gala1-3/4Gal (1K, 1N, 1O, 1P and 2A; see
table 2 for structures) was observed (Figure 1A). The growth of
11168-GS at 37uC under a microaerobic atmosphere, which
mimics mammalian host-like conditions (11168-GS 37uC), and at
42uC under a microaerobic atmosphere, which mimics avian host-
like conditions (11168-GS 42uC), resulted in significantly greater
binding (P,0.05) to terminal Gal structures in comparison to
11168-GS 25uC. In fact, C. jejuni 11168-GS 37uC and 11168-GS
42uC bound all terminal Gal structures present on the array
(Figure 1A). However, structures such as Galb1-3GlcNAc, Galb1-
3GalNAc, Galb1-3GalNAcb1-4Galb1-4Glc and Gala1-3Gal (1A,
E, F and N respectively; Figure 1 and Table 2) were bound
significantly less by 11168-GS 42uC in comparison to 11168-GS
37uC. Conversely, the structure Galb1-4GlcNAcb1-3Galb1-4Glc
(1H, Figure 1 and Table 2) was bound significantly more by
11168-GS 42uC than 11168-GS 37uC. Even though some
differences in the level of binding to various terminal Gal
structures by C. jejuni 11168-GS grown at conditions that mimic
mammalian and avian hosts were noted, there appeared to be no
significant specificity requirement for a particular glycosidic
linkage or underlying sugar.
With respect to Gal terminated glycans, binding of C. jejuni
11168-O (Figure 1B) had few statistically significant differences to
the binding observed for 11168-GS (Figure 1A). For example the
ability of C. jejuni 11168-O to bind terminal Gal structures
generally increased as the growth temperatures increased
(P,0.05). Specific differences however were observed between
the two 11168 isolates grown at 37uC and 42uC. For example,
11168-O 37uC bound glycans 1H, 1I, 1J, 1K and 1M significantly
more than 11168-O 42uC( P ,0.05; Figure 1B). This is different
than binding observed to the same glycans by 11168-GS grown at
37uC and 42uC, where no significant differences were observed
(Figure 1A). Analogous to that observed for 11168-GS binding to
terminal Gal structures, even though some differences in the level
of binding to various terminal Gal structures by C. jejuni 11168-O
grown under mammalian and avian-like conditions were noted, no
significant differences in the specificity for a particular glycosidic
linkage or underlying sugar could be deduced. As with 11168-GS,
11168-O grown at 37uC and 42uC, but not at 25uC had significant
binding to terminal Gala1-3/4Gal structures (Figure 1B).
Binding to Mannose containing glycans
With respect to the ability of C. jejuni 11168 to bind Man-
containing structures, figure 2A shows that C. jejuni 11168-GS
bound multiple Man structures at low but detectable levels
irrespective of the growth conditions tested (Figure 2A). One
exception was the binding of 11168-GS to a1-3-mannobiose
(Mana1-3Man; 5D), which was noticeably reduced. Interestingly,
there were no significant differences observed in the level and
specificity of C. jejuni 11168-O 25uC and 11168-GS 25uC binding
to Man. However, 11168-O grown at conditions mimicking
mammalian and avian hosts had, in the majority of cases,
Table 1. C. jejuni 11168 genome sequenced (11168-GS)
and 11168 original (11168-O) growth and/or maintenance
conditions investigated.
Temperature Atmosphere
Growth/maintenance
time (hrs)
Environment
11168-GS 25uC 20–25uC Normal 24
11168-O 25uC 20–25uC Normal 24
Mammalian
11168-GS 37uC3 7 uC Microaerobic 36
11168-O 37uC3 7 uC Microaerobic 36
Avian
11168-GS 42uC4 2 uC Microaerobic 20
11168-O 42uC4 2 uC Microaerobic 20
doi:10.1371/journal.pone.0004927.t001
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grown under the same conditions. The only exception to this was
11168-O binding to glycans containing GlcNAcb (1-2)Man,
particularly GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3))Man
(5B), an important N-glycan biantennary core structure, which
significantly increased as the growth temperature was increased,
and to a lesser extent 5A (Figure 2B). Considered together, the
data suggests that a distinct difference in Man-binding potential
exists between C. jejuni 11168-GS and 11168-O when grown at
conditions that are associated with either the mammalian or avian
hosts.
Binding to fucoslylated glycans
C. jejuni 11168 showed significant binding to a range of
fucosylated glycans. C. jejuni 11168-GS maintained at 25uC,
bound only approximately 50% of the fucosylated glycans present
on the array (Figure 3A). Of particular note was the fact that no
binding was observed for 11168-GS 25uC to the trisaccharides
Lewis
a (Galb1-3(Fuca1-4)GlcNAc; Le
a; 7J) and Lewis
x (Galb1-
4(Fuca1-3)GlcNAc; Le
x; 7I) (Figure 3A), even though detectable
binding to other glycans terminated with Le
a and Le
x was
observed (e.g. 7B and 7C, respectively). Further analysis found that
11168-GS 25uC bound monofucosylated glycans with a disaccha-
ride backbone (7F, 7G, 7H, 7I, 7J, 7K, 7M, 7O, 8A and 8B) to a
lesser extent than monofucosylated tetrasaccharide or larger
glycans (7A, 7B, 7C, 8C and 8D; P=0.04). As previously observed
for 11168-GS binding to terminal Gal (Figure 1A), 11168-GS
binding to Fuc was also dependent on the growth/maintenance
conditions. That is, fucosylated structures were bound by 11168-
GS 37uC and 11168-GS 42uC to a significantly greater extent than
11168-GS 25uC (Figure 3A).
Even though in comparison to 11168-GS 25uC a larger subset
of fucosylated glycans was bound, C. jejuni 11168-O 25uC like
11168-GS 25uC was unable to recognise Le
a and Le
x (7J and 7I,
respectively; Figure 3B). As was seen for 11168-GS the binding of
11168-O grown at 37uC and 42uC was significantly higher
(P,0.05) than that seen for 11168-O 25uC (Figure 3B). However,
unlike 11168-GS, there was no increase in 11168-O Fuc-binding
as growth conditions were changed from 37uC microaerobic to
42uC microaerobic (Figure 3B). One of the few fucosylated
structures that was poorly bound by 11168-O was sulfo-Le
a (8A,
Figure 3B), which exhibited significantly reduced binding
compared to 11168-GS grown under host-like conditions. These
data highlight distinct differences in Fuc binding that is dependent
both on the C. jejuni isolate (11168-GS or 11168-O), and the
condition used to grow/maintain the bacteria.
Binding to sialylated glycans
Our glycan array analyses also identified significant differences
in the ability of C. jejuni 11168 to bind to Neu5Ac-containing
glycoconjugates, with Neu5Ac-binding being affected not only by
the growth/maintenance conditions, but also the isolate (11168-
GS or 11168-O). Overall, C. jejuni 11168-GS bound all Neu5Ac-
containing glycans present on the array (Figure 4A); however,
increased binding was observed for 11168-GS 37uC and 11168-
GS 42uC in comparison to 11168-GS 25uC( P ,0.05; Figure 4A).
C. jejuni 11168-O maintained at 25uC was also able to recognise
and bind all sialylated glycans. Significantly however, Neu5Ac-
binding was almost completely abolished when C. jejuni 11168-O
was grown at 37uC and 42uC (Figure 4B). The only exception to
this was 11168-O binding to monosialyl, monofucosyllacto-N-
neohexaose (Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-6Galb1-
4GlcNAcb1-3)Galb1-4Glc; 10D; Figure 4B and Table 2), a
fucosylated and sialylated biantennary glycan, which was signif-
icantly higher for 11168-O 37uC and 42uC in comparison to
11168-O 25uC (Figure 4B). It is interesting to note that binding to
sialylated structures was independent of the Neu5Ac linkage (a2-3,
a2-6 or a2-8) and the nature of the sub-terminal sugar for both
11168-GS and 11168-O (Figure 4). Taken together, these data
indicate that significant differences exist between C. jejuni 11168-
GS and 11168-O recognition of sialylated glycans when grown at
conditions that are associated with either the mammalian or avian
hosts.
Recently, a sialidase activity was observed associated with the C.
jejuni CSTII sialyltransferase following its expression in E. coli [28].
Given the differences observed in Neu5Ac-binding between
11168-GS (significant Neu5Ac binding) and 11168-O (little or
no Neu5Ac binding), and that such sialidase activity could release
terminal Neu5Ac from sialylated glycans on the glycan array,
additional array analyses were performed in the presence of the
sialyltransferase inhibitor CMP, and the sialidase inhibitors
Neu5Ac2en and 4-guanidino-Neu5Ac2en (Zanamivir). Represen-
tative experiments were performed using 11168-O 25uC and
11168-GS 42uC. These conditions were chosen to allow for testing
of both strains at their respective maximum observed Neu5Ac
binding capacity. The analyses showed that the addition of these
known inhibitors did not significantly alter the ability of 11168-GS
42uC and 11168-O 25uC to bind Neu5Ac containing glycans
(P.0.52, Figure 5A and B). In fact, the addition of sialyltransferase
and sialidase inhibitors had no effect on any of the glycan binding
profiles shown in figures 1–4 for both C. jejuni 11168-GS 42uC and
11168-O 25uC( P .0.18).
Figure 1. Binding of C. jejuni 11168 to uncapped terminal Gal
structures. Fluorescence intensities associated with C. jejuni 11168-GS
(A) and C. jejuni 11168-O (B) binding to uncapped Gal structures (25uC,
black bar; 37uC, grey bar; and 42uC, white bar). For the structure of the
individual glycans refer to Table 2. * Significantly different to 25uC,
P,0.05; # Significant difference between 37uC and 42uC, P,0.05.
doi:10.1371/journal.pone.0004927.g001
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The specificity of glycan-mediated adherence of C. jejuni 11168
isolates were verified by in vitro Caco-2 binding assays following
pre-treatment of cells with a competing lectin. The lectins selected
were Erythrina cristagalli agglutinin (ECA; Galb1-4Glc/
GlcNAc.Gal), concanavalin A (ConA; Man), Ulex europaeus
agglutinin 1 (UEA-1; terminal a1-2 Fuc), Limax flavus agglutinin
(LFA; terminal sialic acid), Maackia amurensis agglutinin (MAA;
Neu5Aca2-3.Gal) and Sambucus nigra agglutinin (SNA;-
Neu5Aca2-6). The effect of pre-treating Caco-2 cells with selected
lectins on C. jejuni 11168 adherence was determined relative to
binding observed in the absence of lectin, which was set at 100%.
As previously observed by Gaynor et al., (2004), we found that C.
jejuni 11168-O (1.2% of inoculated bacteria) adhered to Caco-2
cells to a greater extent than 11168-GS (0.41% of inoculated
bacteria) (P=0.004) under standard assay conditions (see Mate-
rials and Methods).
We found that treatment with ECA reduced C. jejuni 11168
adherence to terminal lactose/Gal structures present on the
surface of Caco-2 cells. C. jejuni 11168-GS 37uC adherence to
Caco-2 cells pre-treated with ECA was reduced by greater than
85% (P=0.02). No statistically significant difference was observed
Table 2. Glycan structures present on array.
ID Glycan structure
1A Galb1-3GlcNAc
1B Galb1-4GlcNAc
1C Galb1-4Gal
1D Galb1-6GlcNAc
1E Galb1-3GalNAc
1F Galb1-3GalNAcb1-4Galb1-4Glc
1G Galb1-3GlcNAcb1-3Galb1-4Glc
1H Galb1-4GlcNAcb1-3Galb1-4Glc
1I Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc
1J Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc
1K Gala1-4Galb1-4Glc
1L GalNAca1-O-Ser
1M Galb1-3GalNAca1-O-Ser
1N Gala1-3Gal
1O Gala1-3Galb1-4GlcNAc
1P Gala1-3Galb1-4Glc
2A Gala1-3Galb1-4Gala1-3Gal
2B Galb1-6Gal
2C GalNAcb1-3Gal
2D GalNAcb1-4Gal
2E Gala1-4Galb1-4GlcNAc
2F GalNAca1-3Galb1-4Glc
2G Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3)Galb1-4Glc
2H Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc
2I Galb1-3GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4Glc
4A GlcNAcb1-4GlcNAc
4B GlcNAcb1-4GlcNAcb1-4GlcNAc
4C GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAc
4D GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAcb1-4GlcNAc
4E GlcNAcb1-4MurNAc
5A GlcNAcb1-2Man
5B GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Man
5C Mana1-2Man
5D Mana1-3Man
5E Mana1-4Man
5F Mana1-6Man
5G Mana1-6(Mana1-3)Man
5H Mana1-6(Mana1-3)Mana1-6(Mana1-3)Man
7A Fuca1-2Galb1-3GlcNAcb1-3Galb1-4Glc
7B Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4Glc
7C Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4Glc
7D Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4Glc
7E Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)Glc
7F Fuca1-2Gal
7G Fuca1-2Galb1-4Glc
7H Galb1-4(Fuca1-3)Glc
7I Galb1-4(Fuca1-3)GlcNAc
7J Galb1-3(Fuca1-4)GlcNAc
7K GalNAca1-3(Fuca1-2)Gal
7L Fuca1-2Galb1-4(Fuca1-3)Glc
ID Glycan structure
7M Galb1-3(Fuca1-2)Gal
7N Fuca1-2Galb1-4(Fuca1-3)GlcNAc
7O Fuca1-2Galb1-3GlcNAc
7P Fuca1-2Galb1-3(Fuca1-4)GlcNAc
8A SO3-3Galb1-3(Fuca1-4)GlcNAc
8B SO3-3Galb1-4(Fuca1-3)GlcNAc
8C Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4Glc
8D Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc
8E Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc
8F Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-3(Fuca1-4)GlcNAcb1-3)Galb1-
4Glc
10A Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAc
10B Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAc
10C Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4Glc
10D Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3)Galb1-4Glc
10E Neu5Aca2-3Galb1-3(Neu5Aca2-6)GalNAc
10F Fuca1-2Galb1-3(Neu5Aca2-6)GlcNAcb1-3Galb1-4Glc
10G Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4Glc
10H Neu5Aca2-6Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)Glc
10I Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc
10J Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3)Galb1-4Glc
10K Neu5Aca2-3Galb1-4GlcNAc
10L Neu5Aca2-6Galb1-4GlcNAc
10M Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4Glc
10N Galb1-3(Neu5Aca2-6)GlcNAcb1-3Galb1-4Glc
10O Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4Glc
10P Neu5Aca2-3Galb1-3(Neu5Aca2-6)GlcNAcb1-3Galb1-4Glc
11A Neu5Aca2-3Galb1-4Glc
11B Neu5Aca2-6Galb1-4Glc
11C (Neu5Aca2-8Neu5Ac)n
doi:10.1371/journal.pone.0004927.t002
Table 2. Cont.
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reductions of greater than 30% were observed (Figure 6A). C. jejuni
11168-O 42uC binding to Caco-2 cells was also significantly
affected by ECA pre-treatment with a reduction of adherence of
more than 80% observed (P=0.04, Figure 6B). In contrast, the
adherence of 11168-O 25uC and 37uC to pre-treated Caco2 cells
was reduced by less than 10% (Figure 6B).
The affect of C. jejuni adherence to fucosylated structures on
Caco-2 cells was determined using UEA-1. While no significant
inhibition of adherence to UEA-1 pre-treated cells was observed
for 11168-GS and 11168-O at 25uC( P .0.22, Figure 6A and B);
40–100% reduction in adherence of 11168-GS and 11168-O
grown at both 37uC and 42uC was observed (P,0.05, Figure 6A
and B).
Pre-treatment of Caco-2 cells with ConA resulted in greater
than 40% reduction in 11168-GS and 11168-O 25uC (P=0.02
and 0.045, respectively), and 11168-GS 37uC (P=0.01) adherence
(Figure 6A). However, adherence to Caco-2 cells by 11168-O
37uC was not affected (P=0.96) by ConA pre-treatment
(Figure 6B).
Initial cell binding assays using LFA to neutralise all terminal
Neu5Ac residues present on Caco-2 cells were performed to
evaluate the involvement of Neu5Ac on in vitro adherence.
Figure 6A shows that a significant decrease in the adherence to
Caco-2 cells of 11168-GS 25uC (P=0.02) and 11168-GS 37uC
(P=0.04) was observed, with a 75–100% reduction in comparison
to non-treated cells. A reduction of 50% was also observed for
11168-GS 42uC adherence; however, this was not statistically
significant (P=0.09, Figure 6A). Based on these results the
adherence of 11168-GS to Caco-2 cells was further assessed by
pre-treating cells with other sialolectins, MAA and SNA
(Neu5Aca2-3Gal.Gal and Neu5Aca2-6Gal-specific lectins re-
spectively). Both MAA and SNA pre-treatment resulted in
significantly reduced adherence of 11168-GS 25uC (P=0.01 and
0.02, respectively) to Caco-2 cells (Figure 6C). However, only
MAA pre-treatment significantly reduced the adherence of 11168-
GS 37uC to Caco-2 cells (Figure 6A), suggesting that 11168-GS
37uC recognition of Neu5Ac on Caco-2 cells is a2-3 specific.
As expected, pre-treatment of Caco-2 cells with LFA signifi-
cantly reduced the adherence of 11168-O 25uC (P=0.02), while
no significant reduction was observed for 11168-O 37uC (P=1.0)
and 42uC (P=0.21) (Figure 6B). Adherence assays using MAA and
SNA as the neutralising lectin also revealed significant inhibition of
11168-O 25uC (P=0.04 and 0.02, respectively), whereas no
difference was observed with either MAA or SNA for 11168-O
37uC binding (Figure 6B). Taken together, this suggests that
11168, both the original and genome sequenced isolates,
maintained under environmental conditions bind Neu5Ac inde-
pendent of linkage, whereas 11168-GS 37uC predominantly binds
a2-3-linked Neu5Ac.
To further explore the significance of Neu5Ac in C. jejuni 11168
adherence to Caco-2 cells, the effect of Neu5Ac removal by
sialidase treatment of Caco-2 cells was explored. Sialidase
treatment of Caco-2 cells resulted in a 50% reduction in the
adherence of both 11168-GS 25uC and 11168-O 25uC compared
to non-sialidase treated controls (P=0.03 and 0.02 respectively,
Figure 7). Reduction in adherence to sialidase treated Caco-2 cells
Figure 2. Binding of C. jejuni 11168 to Man containing
structures. Fluorescence intensities associated with C. jejuni 11168-
GS (A) and C. jejuni 11168-O (B) binding to Man containing glycans
(25uC, black bar; 37uC, grey bar; and 42uC, white bar). For the structure
of the individual glycans refer to Table 2. * Significantly different to
25uC, P,0.05; # Significant difference between 37uC and 42uC, P,0.05.
doi:10.1371/journal.pone.0004927.g002
Figure 3. Binding of C. jejuni 11168 to fucosylated structures.
Fluorescence intensities associated with C. jejuni 11168-GS (A) and C.
jejuni 11168-O (B) binding to fucosylated glycans (25uC, black bar; 37uC,
grey bar; and 42uC, white bar). For the structure of the individual
glycans refer to Table 2. * Significantly different to 25uC, P,0.05; #
Significant difference between 37uC and 42uC, P,0.05.
doi:10.1371/journal.pone.0004927.g003
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42uC (12% reduction); however, only 11168-GS 37uC was
significantly different to untreated controls (P=0.02, Figure 7).
The opposite was observed for the adherence of 11168-O 37uC
and 42uC to sialidase treated Caco-2 cells with increases of 47%
and 109%, respectively. However, only the increase observed for
11168-O 42uC was significantly different to normal adherence
observed for untreated Caco-2 cells (P=0.04).
Lectin competition combined with sialidase treatment (summa-
rised in Table 3) provided independent verification of the glycan
array data, with inhibition of C. jejuni adherence observed using
lectins specific for Gal-, Fuc-, Man- and Neu5Ac-containing
glycans and differential effects of sialidase treatment being
observed between the C. jejuni 11168 isolates.
Discussion
Bacterial pathogens and commensal organisms both utilise
adherence to host cell surface glycans for colonisation and/or
initiation of disease [2]. In this study we demonstrate that glycan
array technology represents a powerful tool for the identification
and characterisation of novel bacteria-glycoconjugate interactions.
Specifically, we were able to interrogate the carbohydrate binding
potential of two C. jejuni isolates, the genome sequenced and non-
colonising C. jejuni 11168-GS isolate, and the original virulent and
colonising C. jejuni 11168-O isolate. Significantly, a number of
glycans were shown to specifically bind both isolates in a manner
dependent on growth/maintenance conditions, including Man,
Fuc, Gal and Neu5Ac, with each verified using a cell-based
adherence assays (summarised in Table 3).
C. jejuni 11168-GS and 11168-O bound terminal Gal structures
independent of linkage and the nature of the sub-terminal
carbohydrate, with the most significant binding observed at
growth conditions that mimic those of the potential hosts. The
specificity of Gal-binding by C. jejuni was confirmed using cell
adherence assays, where a significant decrease was observed for
11168-GS grown at 37uC and 11168-O grown at 42uC following
pre-treatment of Caco-2 cells with the lectin ECA. It should be
noted that ECA binds lactose with greater affinity than other
terminal Gal-glycans. Therefore, glycan structures similar to the
array glycans 1B, 1G and 1H would be preferentially neutralised
by ECA over other terminal Gal structures (e.g. 1B, 1C, 1D).
Gal-binding lectins are common throughout nature and are
involved in cell-cell and cell-matrix adhesion, cell signaling, toxin
binding and cytokine release [2,29,30,31,32]. Bacterial pathogens
produce a range of Gal-specific lectins that are used in various
ways to interact with the host tissues. Several bacterial toxins target
Gal on cell surfaces [2,32], while other bacteria use Gal-binding
lectins for adhesion, including enteroaggregative and enteropatho-
genic E. coli [33,34,35]. E. coli possesses an adhesin known as
PapG, located on the flexible tip of P fimbriae, which binds Gala1-
4Gal sequences present in the core of glycosphingolipids [36,37].
P. aeruginosa expresses a soluble Gal-specific lectin, PA-IL, which
facilitates adherence to the intestinal epithelium and also leads to
Figure 5. Relative binding of C. jejuni 11168 to Neu5Ac
containing structures in the presence of sialyltransferase and
sialidase inhibitors. Relative fluorescent levels of treated 11168-GS
42uC (A) and C. jejuni 11168-O 25uC (B) compared to normal C. jejuni
binding to Neu5Ac containing glycans. (Neu5Ac2en, black bar; 4-
guanidino-Neu5Ac2en, grey bar; and CMP, white bar). For the structure
of the individual glycans refer to Table 2.
doi:10.1371/journal.pone.0004927.g005
Figure 4. Binding of C. jejuni 11168 to Neu5Ac containing
structures. Fluorescence intensities associated with C. jejuni 11168-GS
(A) and C. jejuni 11168-O (B) binding to Neu5Ac containing glycans
(25uC, black bar; 37uC, grey bar; and 42uC, white bar). For the structure
of the individual glycans refer to Table 2. * Significantly different to
25uC, P,0.05; # Significant difference between 37uC and 42uC, P,0.05.
doi:10.1371/journal.pone.0004927.g004
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nature of the lectin, and the function of Gal-binding by C. jejuni
identified here awaits elucidation. However, our investigations
suggest that C. jejuni NCTC11168 possesses either one Gal- specific
lectin with broad substrate specificity able to bind both a- and b-
linked Gal, or two highly specific lectins able to bind Gala1-3/
4Gal and Galb- linked glycans separately that may be important
for host (mammalian and avian) cell adherence. The finding that
11168-GS and 11168-O maintained at 25uC do not bind Gala1-
3/4Gal sequences further suggests that this structure may be of
particular importance in host adherence.
A previous study by Russell and Blake [39], showed that free
Man was able to inhibit the adherence of C. jejuni to Caco-2 cells;
however, the direct interaction of C. jejuni to Man has not
previously been reported. Our present study has now demonstrat-
ed that C. jejuni 11168 is able to directly bind Man containing
glycans in a specific manner. Interestingly, dramatic differences
were observed between the ability of the GS and O 11168 isolates
to bind Man. C. jejuni 11168-GS was able to bind a wide variety of
Man structures independent of the growth/maintenance condi-
tions. Conversely, C. jejuni 11168-O only bound Man after being
maintained at 25uC under normal oxygen conditions. These
results were confirmed by the ability of the Man-specific lectin
ConA to inhibit the adherence of C. jejuni 11168 to Caco-2. Based
on these findings it is therefore probable that C. jejuni 11168-O
possesses a Man-binding lectin whose expression is dependent on
the environmental temperature and/or atmospheric conditions
encountered. Further, Man-recognition by C. jejuni 11168-O
suggests that Man may be required for initial adherence to host
tissues after environmental challenge, but may not be necessary for
continued colonisation. Man is a ubiquitous component of N-
glycan structures [40], used by many bacterial commensals and
pathogens for adherence, such as uropathogenic E. coli that utilises
the Man-specific lectin FimH located at the tip of type 1 fimbriae
to bind host tissue [11,41]. The vast majority of Man binding
lectins identified in bacteria are, like FimH, associated with
fimbriae or pili, extracellular adhesins that C. jejuni is not known to
possess [42,43]. While the Man-specific lectin of C. jejuni is unlikely
to be of similar structure to previously identified fimbriae or pili
lectins, the broad Man-binding specificity observed in C. jejuni is
commonly observed in other bacterial species [41,44].
It is not surprising that C. jejuni 11168 grown under mammalian
and avian host-like conditions recognized multiple fucosylated
glycans, including Le antigens. Fucosylated glycoproteins are
frequently found in the intestines of humans and other animals
[45], with Le antigens representing a common fucosylated glycan.
Figure 6. Lectin inhibition of C. jejuni adherence to intestinal
cell line. C. jejuni 11168-GS (A) and 11168-O (B) adherence to Caco-2
cells pre-treated with ECA, UEA-1, ConA, LFA, MAA and SNA (25uC, black
bar; 37uC, grey bar; and 42uC, white bar). * Significant difference to non-
lectin treated control, P,0.05; ND, Not determined.
doi:10.1371/journal.pone.0004927.g006
Figure 7. Relative adherence of C. jejuni 11168 to sialidase
treated Caco-2 cells. Relative adherence of 11168-GS (left) and
11168-O (right) to sialidase treated Caco-2 cells with respect to normal
adherence levels (25uC, black bar; 37uC, grey bar; and 42uC, white bar).
doi:10.1371/journal.pone.0004927.g007
Table 3. Summary of C. jejuni 11168-GS and 11168-O binding
to glycan array.
Terminal glycan 11168-GS 11168-O
25uC3 7 uC4 2 uC2 5 uC3 7 uC4 2 uC
Man ++ +++ ++ ++ 22
Le
a + +++ +++ + +++ +++
Le
b + ++ +++ + ++++ ++++
Le
x + +++ +++ + +++ +++
Le
y + ++++ +++ + ++++ ++++
a2-3Neu5Ac ++ ++++ + ++ 22
a2-6Neu5Ac ++ ++++ + ++ 22
Galb1-3/4/6Glc/GlcNAc/Gal 2 ++ ++ + +++ +++
Gala1-4/4Gal 2 ++ ++ + +++ +++
2: Fluorescence ,200 with no reduction in adherence caused by competing
lectin.
+: Fluorescence ,500 with no reduction in adherence caused by competing
lectin.
++: Fluorescence ,500 with significant reduction in adherence caused by
competing lectin.
+++: Fluorescence .500,1000 with significant reduction in adherence caused
by competing lectin.
++++: Fluorescence ,1000 with significant reduction in adherence caused by
competing lectin.
doi:10.1371/journal.pone.0004927.t003
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a and Le
b) or type 2
structures (Le
x and Le
y) and are present, together with other
fucosylated glycans, on mucins of the gastrointestinal tract [46].
Fucosylated glycans and free Fuc have been shown to interact with
C. jejuni [24,26]. In fact, free Fuc and Fuc associated with the O-
glycans of mucins are considered C. jejuni chemotaxis agents [24].
It is therefore likely that C. jejuni proteins involved in chemotaxis
towards Fuc may be, at least in part, responsible for the binding of
C. jejuni to fucosylated structures present on our glycan array.
The ability of bacteria to bind to fucosylated host cell glycans
has been linked to pathogenesis, with P. aeruginosa representing a
well-characterised example. The P. aeruginosa Fuc-specific lectin
(PA-IIL) has been structurally elucidated, and been shown to play
a central role in Pseudomonas infection of immuno-compromised
and cystic fibrosis patients [47]. PA-IIL facilitates the colonisation
of the airways by adhering to the heavily fucosylated mucosal layer
[47]. In C. jejuni, a mucosal pathogen, the importance of Fuc-
containing glycoconjugates, particularly fucosylated glycoproteins
found in human milk, was demonstrated by the ability of these
structures to protect individuals against C. jejuni infection [48]. This
protection against infection was attributed to the binding of C.
jejuni to difucosylated terminal Le
b structures and 2’fucosyllactose
present on human milk glycoproteins [26]. The importance of this
interaction is highlighted by our observation that 11168-GS and
11168-O were able to bind at least one of the terminal Le
b or
2’fucosyllactose structures on our glycan array independent of the
growth/maintenance conditions tested (Table 3, Figure 3A and
3B). Further, the complete inhibition of C. jejuni 11168-O 37uC
adherence to Caco-2 cells by UEA-1 (terminal a1-2 Fuc binding
lectin) confirmed the binding specificity of C. jejuni to terminal
monofucosylated structures such as 2’ fucosyllactose. It should be
noted that C. jejuni 11168-O grown under mammalian host-like
conditions was a poor binder of other non-Fuc capped glycans.
However, the binding of lectins to a specific site on a cell surface
glycoprotein may also result in the occlusion of other sites used by
adhering bacteria, leading to a further decrease in binding to host
cells.
The differential binding of fucosylated structures by C. jejuni
grown or maintained under different conditions was also
demonstrated by both the glycan array and UEA-1 pre-treatment
of Caco-2 cells, with the most striking differences observed for
both 11168-GS and 11168-O maintained at 25uC. Little or no
binding was seen for both Le
a and Le
x under environmental
conditions, with many other fucosylated structures showing
reduced binding when compared to bacteria grown under host-
like conditions. UEA-1 pre-treatment of Caco-2 cells had no effect
on the level of adherence of environmentally maintained 11168.
These data suggest that environmentally maintained C. jejuni
11168 is a poor binder of terminally a1-2 fucosylated structures
compared to the same bacteria grown under host-like conditions.
These results not only highlight the importance of host glycan
fucosylation for C. jejuni adherence to intestinal cells, but also that
C. jejuni grown under host like conditions is likely to express a
broad specificity Fuc-binding lectin that mediates this interaction.
Much like Man-recognition, binding to sialylated glycans was
observed for C. jejuni 11168-GS regardless of growth/maintenance
conditions and for 11168-O 25uC, with little or no binding
observed for 11168-O when grown under conditions mimicking
mammalian or avian host (Table 3, Figure 4A and 4B).
Significantly, these differences between C. jejuni 11168-GS and
11168-O are not due to a modification of glycans by the action of
a recently described C. jejuni sialyltransferase/sialidase activity
[28], with no significant differences in Neu5Ac binding observed
in the presence of sialyltransferase or sialidase inhibitors.
As proposed for Man-binding, Neu5Ac may be important for
the initial contact between environmental C. jejuni and host tissues.
Neu5Ac is another highly abundant carbohydrate on cell surface
glycoconjugates, representing a common receptor for lectins
expressed by many pathogenic bacteria species and viruses [49].
Cell surface mucins are typically highly sialylated, only becoming
fucosylated in disease states such as cystic fibrosis where there is
large turnover of cell surface components, including cell surface
mucins [47,50]. The binding of C. jejuni to Neu5Ac-containing
glycans present on our array was found not to be dependent on
Neu5Ac-linkage or the nature of the sub-terminal sugar, regardless
of the growth conditions tested and this was confirmed by LFA
adhesion neutralisation assays. However, analyses using the
Neu5Ac-linkage specific lectins SNA and MAA revealed selective
specificity for a2-3-linked Neu5Ac, but only for C. jejuni 11168-GS
grown at 37uC (Figure 5A).
Sialidase treatment of Caco-2 cells further verified the role of
Neu5Ac in the adherence of C. jejuni 11168 maintained under
environmental conditions with significant reduction in adherence
observed for 11168-GS 25uC and 11168-O 25uC. A significant
reduction in the adherence of 11168-GS 37uC was also observed
verifying the array and Neu5Ac-binding lectin competition data.
Sialidase treatment of Caco-2 cells also affected adherence of
11168-O grown under host-like conditions; however, unlike
11168-GS an increase in adherence was observed. Caco-2 cells
have been shown to express a2-3Neu5Ac, a2-6Neu5Ac, a1-2Fuc
and Gal, with terminal Neu5Ac structures consistently being
reported in all studies [51,52,53,54,55]. Treatment with sialidase,
thus removing terminal Neu5Ac residues, would therefore unmask
sub-terminal structures such as Le
x, lactose and neo-lactose
[51,52,53,55] enabling these glycans to be bound by C. jejuni.
The observed increase in adherence of C. jejuni 11168-O 37uC and
42uC is therefore likely to be due to an increase in the number of
these newly liberated glycans on the surface of Caco-2 cells
following sialidase treatment. This is supported by the glycan array
analysis that showed that Le
x, lactose and neo-lactose were
strongly bound by 11168-O grown under host like conditions
(Table 3). These results indicate that 11168-O grown under host-
like conditions is more likely to adhere to niches of the
gastrointestinal tract with lower levels of sialylated glycoconjugates
in comparison to either 11168-GS or environmentally challenged
11168-O.
Throughout this study both isolates of C. jejuni 11168 bound
type-1 (Galb1-3GlcNAc, Le
a and Le
b) and type-2 (Galb1-
4GlcNAc, Le
x and Le
y) structures present on the array. This is
of interest as type-2 glycans are ubiquitously distributed through-
out tissues of the body, while type-1 glycans are expressed only
within certain tissues including the digestive tract and pancreatic
tissues [56]. The binding of type-1 glycans is to be expected as C.
jejuni primarily infects/colonises the gastrointestinal tract of
animals; however, in human disease C. jejuni is known to also
cause systemic infections including meningitis and urinary tract
infections. The ability of C. jejuni to bind type-2 glycans may be an
important virulence factor in systemic C. jejuni infections.
With the exception of fucosylated structures such as Le
b, very
little was previously known about the glycans recognised by C.
jejuni. Our study has now identified a number of additional
carbohydrate structures commonly found on the mucins of the
gastrointestinal tract that are bound by both the original C. jejuni
NCTC11168 (11168-O) and genome sequenced (11168-GS)
isolates. Glycan array and cell adhesion assays indicate that these
newly identified glycan-bacteria interactions are important for
adhesion and possibly colonisation of host tissues during both
infection and commensal colonisation.
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11168-O highlights an apparent adaptation of glycan binding
potential from environmental to host-like conditions, with Gal/
Fuc binding being associated with host-like conditions and Man/
Neu5Ac being associated with environmental conditions (summa-
rised in Table 3). This indicates that C. jejuni 11168-O has a
preference for gastrointestinal niches within host tissues, with
terminal Gal/Fuc being preferentially bound over Man/Neu5Ac.
The most striking difference observed through our analyses was
that the Man/Neu5Ac binding specificity of the C. jejuni 11168-O
isolate varied significantly according to growth conditions, whereas
this was not the case for the C. jejuni 11168-GS isolate. Much like
11168-O, C. jejuni 11168-GS grown under host conditions was
observed to have increased binding to Gal/Fuc compared to
environmentally maintained 11168-GS; however, 11168-GS
grown under host like conditions still bound Man/Neu5Ac
(Table 3). Therefore, given the data presented here, we postulate
that the binding of Man/Neu5Ac may provide the initial
interactions important for colonisation following environmental
exposure. These interactions occur prior to bacteria adaptation
through the expression of factors necessary for survival and growth
in the avian and mammalian host. Presumably, changes in
carbohydrate specificity from Man/Neu5Ac to Fuc/Gal through
the expression of alternate lectins may then allow C. jejuni to
adhere and colonise its preferred gastrointestinal niche.
Differential binding of glycans reported here, is likely to be one
of several contributing factors to the differences in colonisation
potential reported for the two C. jejuni 11168 isolates. [21]. Other
factors contributing to the apparent lack of adaptation of C. jejuni
11168-GS to host-like conditions need to be considered, such as
reduced motility of 11168-GS compared to 11168-O, and
differences in the expression of genes involved in respiration
(modulating C. jejuni’s response to oxygen levels) and metabolism
(modulating C. jejuni’s response to temperature fluctuations) [21].
This report highlights the importance of further and detailed
exploration of glycan-lectin interactions in the initiation and
maintenance of C. jejuni colonisation and infection.
Materials and Methods
Preparation of SuperAmine Glass Slides
Propylamino-glass slides (SuperAmine2 glass slides, ArrayIt
Microarray Technologies) were functionalised with a polyethylene
glycol spacer moiety as previously described [57]. Glass slides were
incubated for at least 18 h in a solution of Fmoc-8-amino-3,6-
dioxaoctanoic acid (10 mM), PyBOP (10 mM), diisopropylethyla-
mine (20 mM) in dry DMF at room temperature in an anhydrous
environment. After fuctionalization the slides were rinsed in DMF,
the Fmoc protecting group removed by incubating the slides in
piperidine (10% v/v) in DMF for 30 min, and the slides were
subsequently rinsed in DMF. The slides were then activated with
isocyanate functionality by incubation in a DMF solution of 1,6-
diisocyanatohexane (10% v/v) for 30 min at room temperature,
rinsed once in DMF, once in THF, and centrifuged dry (1000 rpm
for 2 min). The slides were stored under vacuum in desiccator for
up to 1 week prior to use.
Preparation of Glycosylamines
Glycans were purchased from Dextra Laboratories (Reading,
UK) and Glycoseparations (Moscow, Russia), and functionalised
with an amine group using a modification of a previously
described methodology by Vetter and Gallop [58]. One to five
milligrams of each glycan and ammonium carbonate (1.3
equivalents) were dissolved in ,25% ammonium hydroxide
(500 mL) in a sealed glass vial and incubated at 50uC for 3 days.
The vials were unsealed, allowed to remain at 50uC for 2 h to
dissipate excess ammonia and carbon dioxide, frozen and
concentrated by lyophilisation. The glycosylamines were subse-
quently dissolved in anhydrous DMSO (100 mL), diluted further
with an equal volume of anhydrous DMF and stored in sealed vials
at 4uC until required.
Preparation of Glycan Arrays
Arrays were printed by the robotic non-contact dispensing
(Piezorray Non-Contact Dispensing System, PerkinElmer) of
1500 pL of 10 mM glycosylamines in DMSO/DMF (1:1) onto
isocyanate functionalised glass slides in replicates of four. Two
identical sub-arrays were printed per slide with each sub-array
comprising 352 spots (80 glycans and 8 controls in replicates of 4).
Once the arrays had been printed they were placed in a vacuum
desiccator fitted with a gas tap, which was evacuated under high
vacuum. The vacuum was sealed off and a round-bottomed flask
containing pyridine (,1 mL) attached via hosing and the
desiccator was re-equilibrated with catalytic pyridine vapour for
at least 8 h. The slides were then neutralised by incubating them
in ethylene glycol (1 M) and pyridine (1% v/v) in DMF for 30 min
at room temperature. The glycan array slides were rinsed in DMF,
then ethanol and centrifuged dry (900 rpm for 2 min), at which
stage they were ready for binding assays.
Bacterial Growth Conditions
C. jejuni strain 11168 original (11168-O; Skirrow), obtained from
Prof Diane Newell (Veterinary Laboratory Agency, London, UK),
and genome sequenced strain (11168-GS; NCTC) were grown at
either 37uCo r4 2 uC for 36 h or 20 h, respectively (see Table 1), on
Columbia agar supplemented with 5% defibrinated horse blood in
microaerobic conditions (10% CO2,5 %O 2 in N2). For the
maintenance of 11168-O and 11168-GS under environmental
conditions bacteria were first grown at 42uC for 20 h prior to
being harvested in 10 mL of sterile fresh pond water and
incubated at 25uC as described in Table 1. Gram-staining was
performed as per standard procedures, and was used to assess the
level of coccoid bacteria present following growth/maintenance at
the conditions stated in Table 1. Only C. jejuni maintained under
environmental conditions were used in further experiments when
bacteria were found to be coccoid.
Labelling of Campylobacter jejuni
C. jejuni were harvested from agar plates using 1 mL of pre-
warmed Brucella broth and pelleted by centrifugation at
13,000 rpm for 1 min. The pellet was washed 5 times with pre-
warmed phosphate buffered saline pH 7.4 (PBS) to remove
residual broth and agar, and diluted in PBS to 10
6 bacteria/
mL. To label 10
6 bacteria, 1 mL of diluted C. jejuni was pelleted by
centrifugation at 13,000 rpm for 2 min and resuspended in
500 mLo f5mM Carboxyfluorescein diacetate, succinimidyl ester
(CFDA-SE, Molecular Probes) prepared in PBS and the labelling
was performed using a modified version of that previously
described [59]. Bacteria were then incubated protected from light
either at room temperature for 90 min or at 37uCo r4 2 uC for
30 min. Excess dye was removed by eight consecutive washes with
1 mL of PBS, with the final pellet being resuspended in 1 mL of
PBS. Initial testing of CFDA-SE labelling was analysed with
fluorescence activated cell sorting (FACS Calibur BD Scientific)
with greater than 99% labelling observed. The extent of CFDA-
labelling was routinely checked by fluorescence microscopy, with
only bacterial samples observed to be greater than 90% labelling
being used in subsequent experiments.
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Each of the two sub-arrays printed per slide were isolated with a
1.762.8 cm (125 mL) Gene Frame (Abgene), into which 125 mLo f
CFDA-labelled bacteria in PBS was added. Studies of the effects of
sialyltransferase and sialidase inhibitors were preformed in the
presence of CMP, Neu5Ac2en and 4-guanidino-Neu5Ac2en
(Zanamivir) at a concentration of 10 mM in PBS. Each sub-array
was covered with a Gene Frame coverslip (Abgene) and incubated
in a humidified chamber at 37uC for 30 min. Slides were washed
with 40 mL of pre-warmed PBS flushed across the array with a
transfer pipette. Duplicate arrays were performed using separate
cultures of the bacterial strains under investigation.
Image Acquisition and Data Processing
Fluorescence intensities of array spots were measured using the
ProScanArray Microarray 4-Laser Scanner (PerkinElmer) using
the Blue Argon 488 excitation laser set to the FITC setting (494
excitation and 518 emission). Image analysis was carried our using
the ProScanArray imaging software ScanArray Express (Perki-
nElmer). Microsoft Excel was used to further process the data and
to perform statistical analysis (Independent sample T test).
Caco-2 Cell Adherence and Lectin Neutralisation Assays
Adherence assays were performed using Caco-2 human
intestinal cell lines. Cells were seeded at 10
5 cells/well in a 96-
well cell culture plates in minimal essential medium (MEM) for
48–72 h prior to bacterial challenge. Caco-2 cells were monitored
prior to the assay to ensure a confluent monolayer of cells and that
the cells had formed tight junctions. Sialidase pre-treatment of
cells was carried out using 50 mU of Vibrio cholerae Sialidase
(Sigma-Aldrich) for 2 h at 37uC in 5%CO2. Cells were pre-treated
with the lectins UEA-1 (Sigma), ConA, ECA, MAA, SNA and
LFA (EY Laboratories, Inc.) for 1 h, and subsequently washed 3
times with PBS. C. jejuni 11168, grown as described above, was
added at a concentration of 5610
6 bacteria per well (viable counts
were performed to verify the inoculums). Bacterial adherence was
allowed to proceed for 1 h at 37uC under microaerobic conditions,
with cells being subsequently washed three times with PBS. Caco-
2 cells were then lysed with 0.1% Triton-X 100 in PBS and
adherent bacteria enumerated by viable counts following plating
onto Columbia agar with 5% horse blood and grown at 42uC for
36 h. All experiments were repeated a minimum of 3 times.
Statistical analysis (independent sample Ttest) of viable bacterial
counts was performed with Microsoft Excel.
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